Sun Pharma And Aurobindo Recall Medications From US Markets

The US Food & Drug Administration reports that major pharmaceutical companies Sun Pharmaceutical Industries and Aurobindo Pharma are recalling items from the US market because of production problems.

According to the most recent Enforcement Report issued by the American health agency, Sun Pharma’s US-based business is recalling 69,707 cartons of Cequa (cyclosporine ophthalmic solution) from the US market.

The medicine is prescribed to treat dry eyes.

USFDA reported, “New Jersey-based Sun Pharmaceutical Industries Inc is recalling the product for being Subpotent”.

On September 7, this year, the business began a countrywide (US) Class III recall.

A Class III recall is issued when the use of, or exposure to, a violative product is not likely to cause adverse health consequences, according to the USFDA.

According to the US Food and Drug Administration, Aurobindo Pharma is recalling 9,890 bottles of Rasagiline Tablets, a drug used to treat Parkinson’s disease, from the United States.

“New Jersey-based Aurobindo Pharma USA Inc, a unit of the Hyderabad-based drug major, is recalling the affected lot due to Failed dissolution specifications”, the USFDA continued.

On August 2, this year, the business began the Class II recall in the United States.

With a current market size of over $50 billion, India’s pharmaceutical business is the third largest in the world by volume.

In 2021-22, India exported medicines worth Rs. 1,75,040 crore, comprising bulk medications and drug intermediates.

Also read: Air India Cancels Flights To Tel Aviv, Israel, Until October 14